In line with our vision to be significant global player by 2010 A.D., Cadila Pharmaceuticals is fast emerging as a true Indian multinational.
As part of our strategy, we have wholly owned subsidiaries, joint ventures, strategic alliances, contract manufacturing, own marketing offices in 4 countries and have significant presence in over 46 countries across the globe. Our business revolves around the exports of formulations, bulk actives, hospital disposables, veterinary formulations and pharmaceutical machinery manufacturing.
Besides a significant presence in the Americas, CIS Countries, Africa, Central and South-East Asia, Oceanic Countries, Japan, Middle East and Europe, the company has offices in USA, Japan, Kenya, Nigeria, Russia, Kazakhstan and Ukraine. The International SBU plans to expand operations to more than 100 countries by 2010.
The focus is on building brands in the following therapeutic segments:

• Anti-Infective
• Gastrointestinal
• Analgesic/Anti-inflammatory
• Cardiovascular
• Respiratory
• Ophthalmology
• Bio-technical Products

Alliances exist with regional majors in the form of International marketing, joint ventures and contract manufacturing. More such collaborations are underway to expand supply chain network and facilitate extensive market coverage. An ultra-modern formulations manufacturing facility conforming to the exacting standards of WHO-GMP, USFDA, MHRA-UK, MCC-South Africa, TGA-Australia, ANVISA- Brazil, EU GMP, ISO 9002 and Japanese GMP is a value-addition to the International SBU in flexing its muscles in the overseas arena. This SBU has been honoured with the Chemexcil Award, 2000-01 and Niryat Shree Award from FIEO, for the year 2001-02.
With its basic philosophy of giving the best to the world at an affordable price, Cadila Pharmaceuticals continues to make a difference in the lives of millions, while carving a niche for Indian Pharmaceuticals exports, globally.